Therapy-related acute promyelocytic leukemia with t(15;17) (q22;q12) following chemotherapy with drugs targeting DNA topoisomerase II. A report of two cases and a review of the literature

Annals of Oncology : Official Journal of the European Society for Medical Oncology
L HoffmannF R Hirsch

Abstract

The development of therapy-related acute myeloid leukemia (t-AML) with balanced translocations to chromosome bands 11q23 and 21q22 has recently been significantly related to previous treatment with several cytostatic drugs poisoning DNA topoisomerase II. A similar association was suspected for other balanced chromosomal aberrations such as the t(15;17) characteristic of acute promyelocytic leukemia (APL). Two cases of acute promyelocytic leukemia were observed following treatment for seminoma with etoposide, cisplatin, and bleomycin and treatment for breast cancer with 4-epi-doxorubicin and subsequent cyclophosphamide, methotrexate, and 5-fluorouracil followed by radiotherapy. Both cases presented a t(15;17) (q22;q12) and were examined for the characteristic chimeric rearrangement of the RAR alpha and PML genes observed in acute promyelocytic leukemia de-novo. In both cases the characteristic chimeric rearrangement was demonstrated. Case no. 2 in addition to the t(15;17) showed an inversion of the long arm of a chromosome no. 5 and a del(7)(q22) in all abnormal mitoses studied. Despite these findings the patient obtained a complete morphological and cytogenetic remission of the leukemia following treatment with all-trans-retino...Continue Reading

Citations

Jun 24, 2000·Leukemia·P M CarliM Maynadié
May 30, 2001·Leukemia & Lymphoma·G LeoneL Pagano
Dec 4, 2003·Bone Marrow Transplantation·N KrögerUNKNOWN University of California, San Francisco
Aug 10, 2007·Journal of Toxicology and Environmental Health. Part B, Critical Reviews·David W PyattSean M Hays
Mar 4, 2011·Pediatric Blood & Cancer·Srividya SathiyamoorthyMetin Ozdemirli
Jan 1, 2003·Genes, Chromosomes & Cancer·Andreas ReiterNicholas C P Cross
Dec 1, 2001·Transplantation·C A DotiL M Aledort
Feb 9, 2002·American Journal of Hematology·Shigeki ItohShin-ichiro Kuriya
Sep 25, 2015·Mutagenesis·Sabry M AttiaSaleh A Bakheet
Jun 2, 2006·Critical Reviews in Toxicology·Robert GoldenPeter G Shields
Mar 6, 2002·Blood·Jens Pedersen-BjergaardClaus Nerlov
May 31, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·M BeaumontP Fenaux
Jan 1, 1996·Drug Delivery·T L Whateley
Oct 16, 2012·International Journal of Environmental Research and Public Health·Ida CasorelliMargherita Bignami
Jun 27, 2009·Leukemia & Lymphoma·Savina Maria Luciana AversaFausto Adami
Jun 18, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Claudio PragaDavid Rogers

❮ Previous
Next ❯

Related Concepts

Related Feeds

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.